Evidence map›Paper›PMID 42903224›Full record

ReviewThe Lancet regional health. Southeast Asia2026

The epidemiology of thalassaemia syndromes in Southeast Asia.

Frédéric B Piel, Suthat Fucharoen, Mohammad Sorowar Hossain, Kittiphong Paiboonsukwong, Anuja Premawardhena, Bishow N Adhikari, Ne Win, Fathmath Jeehan Saleem, Gregorio Rangel, Roshan Colah

Abstract readReview
In one paragraph

Review in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Frédéric B PielDepartment of Epidemiology & Biostatistics, School of Public Health, Imperial College London, London, UK.
Suthat FucharoenThalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Salaya, Nakhon Pathom, Thailand.
Mohammad Sorowar HossainDepartment of Emerging and Neglected Diseases, Biomedical Research Foundation, Dhaka, Bangladesh.
Kittiphong PaiboonsukwongThalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Salaya, Nakhon Pathom, Thailand.
Anuja PremawardhenaDepartment of Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.
Bishow N AdhikariDepartment of Paediatrics, Kanti Children's Hospital, Maharajgunj, Kathmandu, Nepal.
Ne WinNational Blood Center and National Health Laboratory, Yangon, Myanmar.
Fathmath Jeehan SaleemMaldivian Thalassaemia Society, Malé, Maldives.
Gregorio RangelInstituto de Ciéncias da Saúde, Dili, Timor-Leste.
Roshan ColahNational Institute of Immunohaematology, Indian Council of Medical Research, Mumbai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thalassaemia syndromes are inherited haemoglobin disorders caused by mutations affecting α- and β-globin chains, ranging in severity from asymptomatic to transfusion-dependent. This Series paper synthesises epidemiological data across ten WHO Southeast Asia Region (SEAR) countries, combining local expertise with a rapid literature review. Due to the high prevalence of α- and β-thalassaemia variants, as well as haemoglobin E, the SEAR carries a disproportionately high burden and faces specific challenges. Although a small number of mutations tends to dominate in each country, the range of underlying mutations and deletions is complex. Beyond molecular studies, epidemiological data remain limited in most SEAR countries. Key challenges include blood supply shortages, consanguinity, gender-based disparities in healthcare access, population migration redistributing mutation profiles, and poor awareness. Recommendations to reduce the health burden of thalassaemia syndromes in the SEAR include setting up national registries, expanding premarital and prenatal screening, improving blood supply coordination, and promoting culturally sensitive education. Without targeted investments and policy commitment, most SEAR populations will remain unable to benefit from recent therapeutic advances, including emerging gene therapies.

Indexed as

Blood transfusionGeneticsHaemoglobinopathyIncidenceMortalityPrevalenceScreening

Identifiers

PMID42903224
PMCPMC13680629

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.